
2022 LIFE SCIENCES DEALMAKING SYMPOSIUM & INVESTMENT FORUM

APRIL 28 – 29, 2022

INTERCONTINENTAL BOSTON



mwe.com/LSDS22

JOIN US

We live in a new world transformed by the pandemic. The life sciences industry has been instrumental in addressing the challenges posed by this global health crisis; and we have all witnessed firsthand the accelerated advances in science and new methods for rapidly developing and deploying new therapies and diagnostics. Investment and dealmaking in the sector continues unabated. Gain the clarity you need to make all the right moves during in-depth and insightful panels from leading life sciences dealmakers, investors, executives and technical experts while forging new connections through exceptional networking opportunities at our tenth Life Sciences Dealmaking Symposium & Investment Forum.

At this must-attend event, you can explore the critical business, transactional and regulatory issues that impact growth and profitability across life sciences with panelists sharing their insights. As an additional offer for investment professionals in the life sciences space, take advantage of our bootcamp for a closer look at the critical issues facing the industry from venture debt to collaborating with CVCs on investments and more during our Life Sciences Investment Forum.

Don't miss this outstanding opportunity to once again connect in-person with many of the life sciences industry's movers and shakers in Boston this Spring.

DRESS CODE

Business casual attire is recommended for this program

AGENDA

THURSDAY, APRIL 28, 2022
LIFE SCIENCES DEALMAKING SYMPOSIUM

All times are displayed in EDT

7:30 – 8:45 am — *REGISTRATION, NETWORKING BREAKFAST & WOMEN'S EVENT*

8:45 – 9:00 am — WELCOMING REMARKS

- Vernessa Pollard, Partner & Co-Chair of Life Sciences, McDermott Will & Emery
- Doug Carsten, Partner & Co-Chair of Life Sciences, McDermott Will & Emery

9:00 – 9:45 am — M&A OUTLOOK: TRANSFORMATIONAL DEALS IN AN EVOLVING ENVIRONMENT

The last two years have brought unprecedented challenges and unique opportunities for dealmakers in the life sciences industry. This opening panel will focus on the latest trends in life sciences M&A and set the stage for the rest of the day's discussion.

- Dennis Crowley, Executive Vice President, Corporate Development, Corza Medical
- Perry De Fazio, Vice President, Convington Associates
- Luba Greenwood, CEO, Kojin Therapeutics
- Jeff Schwartz, Managing Director, Life Sciences, Bain Capital
- Jonas Svedlund, Vice President & Deputy General Counsel, Thermo Fisher Scientific Technology Association

MODERATOR: Byron Kalogerou, Partner, McDermott Will & Emery

AGENDA

THURSDAY, APRIL 28, 2022
LIFE SCIENCES DEALMAKING SYMPOSIUM

All times are displayed in EDT

9:45 – 10:30 am — DEALMAKING IN DIGITAL HEALTH & AI

Artificial Intelligence (AI) and Virtual Reality (VR) are more than buzzwords – meet three innovative CEOs that are bringing technologies to market that successfully incorporate AI or VR in order to improve diagnostics, clinical decision making and patient treatment.

- Dale Van Demark, Partner, McDermott Will & Emery
- Aaron Gani, Founder & CEO, BehaVR
- Richie Bavasso, Co-Founder & CEO, nQ Medical
- Wasim Malik, Managing Partner, Iaso Ventures
- Marina Massingham, CEO, Aifred Health

MODERATOR: Jiayan Chen, Partner, McDermott Will & Emery

10:30 – 10:45 am — *NETWORKING BREAK*

10:45 – 11:30 am — INVESTMENT TRENDS

The difficult IPO market and other global economic and geo-political factors signal choppy waters ahead, but there is continuing private investment in the life sciences sector countering these macro factors (for now). Our panel of experienced investors and executives will discuss where investment dollars are currently going and factors that investors will be considering as they source and vet new investment opportunities.

- Jens Bitsch-Norhave, Vice President, Transactions, J&J Innovation
- Nancy Briefs, Co-Founder, President & CEO, AltrixBio
- Alex Gasner, Executive Vice President, Roivant Health
- Bruce Robertson, Managing Director, H.I.G. BioHealth Partners
- Stefan Spazek, EVP & Director of Debt Placement, Capital Advisors Group

MODERATOR: Mark Mihanovic, Partner & Co-Head of Transactions, McDermott Will & Emery

11:30 am – 12:15 pm — CROSS-BORDER COLLABORATION & DEALMAKING

International collaboration is on the rise, as companies large and small look for partners and acquisition targets through a global lens. It's an increasingly small world, and this panel will discuss trends to look out for in the year ahead.

- Michael Bayewitch, Executive Director, International Business Development, Simcere Pharma
- Somjeet Dey, Business Development Operations, Otsuka
- Deniz Razon, Chief Business Officer, Servier Pharmaceuticals
- Mark Stencik, Head of Transactions & Executive Director, Business Development, Merck

MODERATOR: Emmanuelle Trombe, Partner, McDermott Will & Emery

12:15 – 1:30 pm — *NETWORKING LUNCHEON & REMARKS*

- Brian Johnson, President, MassMEDIC

AGENDA

THURSDAY, APRIL 28, 2022

TRACK 1 | IN-HOUSE COUNSEL TRACK

All times are displayed in EDT

1:30 – 2:15 pm

NAVIGATING DIAGNOSTIC DEALS

Will the recent and rapid explosion in diagnostics startups and testing infrastructure lead to a round of consolidation in the industry? This panel will explore what's ahead.

- Alidad Mireskandari, Chief Development Officer, Interpace Diagnostics
- Alif Saleh, CEO, Scipher Medicine
- Michael Siekman, Partner, McDermott Will & Emery
- Karen Tepichin, General Counsel, Ginkgo Bioworks

MODERATOR: Mike Ryan, Partner, McDermott Will & Emery

2:15 – 3:00 pm

PRESSURE POINTS IN LICENSING & COLLABORATION TRANSACTIONS

You think you've found the right partner, now how do you put the right agreement in place to capitalize on the opportunity? This panel will focus on the key commercial and legal considerations involved, and what you can expect to be the biggest areas of contention once negotiations are underway.

- Sree Kant, Founder & CEO, BAKX
- Imran Nasrullah, Head of Licensing, Bayer
- John Urquhart, Senior Managing Director, Healthcare Royalty Partners
- Sally Wang, VP of Business Development & Head of Global Business Unit, PepLib
- Michael Wolf, Vice President & Deputy General Counsel, Baxter

MODERATOR: David Santangelo, Partner, McDermott Will & Emery

3:00 – 3:15 pm

NETWORKING BREAK

3:15 – 4:00 pm

WHEN DEALS GO AWRY: NAVIGATING DISPUTES IN LIFE SCIENCES TRANSACTIONS

What do you do when it doesn't work out? These panelists will discuss how to avoid and manage disputes in life sciences transactions.

- Anna Elliott, Managing Director & Partner, Vertess
- John Mayfield, Vice President, Corporate & Business Development, EQRx
- Vipul Patel, Managing Director, AON M&A and Transaction Solutions
- Michael Sheehan, Partner, McDermott Will & Emery

MODERATOR: Michael Darowski, Partner, McDermott Will & Emery

4:00 – 4:45 pm

INTERNATIONALIZING A LIFE SCIENCES COMPANY

This panel will discuss priorities and considerations for in-house counsel when taking a US-based company international, with a focus on the UK and EU markets.

- Sharon Lamb, Partner, McDermott Will & Emery
- Paul Fehlner, Senior Vice President, Chief Legal Officer & Corporate Secretary, Axcella
- Joel Gross, Principal, Specialized Tax Services Group, BDO

MODERATOR: Gary Howes, Counsel, McDermott Will & Emery

4:45 – 6:30 pm

NETWORKING COCKTAIL RECEPTION

AGENDA

THURSDAY, APRIL 28, 2022

TRACK 2 | BUSINESS DEVELOPMENT & INVESTOR TRACK

All times are displayed in EDT

1:30 – 2:15 pm

WHAT'S AHEAD IN TELEHEALTH & REMOTE PATIENT MONITORING

Will the pivot to virtual care be a temporary trend or a permanent shift in care delivery? This panel will explore how virtual care has changed the healthcare and life sciences industries, and the impact that government and private payer reimbursement will have on this fast-growing sector.

- Marshall Jackson, Partner, McDermott Will & Emery
- Meryl Holt, Senior Counsel, Cadence
- Sean Kinsman, Chief Clinical Officer, RecoveryOne
- Milan Shah, Chief Technology Officer, Biofourmis

MODERATOR: Lisa Mazur, Partner & Co-Chair of Digital Health, McDermott Will & Emery

2:15 – 3:00 pm

PRIVATE EQUITY & ACCELERATION CAPITAL

Private equity investment is flowing into the life sciences services sector but where will the dollars go in the year ahead? This panel will discuss the role that private equity will play in the industry's ongoing growth.

- Eleanor West, Partner, McDermott Will & Emery
- Jonathan Behr, Partner, SV Health Investors
- J.C. Wetzel, Director, Thompson Street Capital Partners

MODERATOR: Krist Werling, Partner & Co-Head for Private Equity, McDermott Will & Emery

3:00 – 3:15 pm

NETWORKING BREAK

3:15 – 4:00 pm

DUE DILIGENCE FOR LIFE SCIENCES TRANSACTIONS

The benefit of the bargain. This panel will discuss strategies for ensuring you get what you pay for in a life science transactions.

- Neal Gordon, PhD, Manging Director, Bioprocess Technology Group, BDO
- Ashleigh Kyle, Associate General Counsel, Becton Dickinson
- Sapna Mehtani, Lead Counsel, IP, Takeda
- Audrey Rojas, Co-Leader, US Risk Transaction Advisory Services, Aon
- Marc Viscogliosi, Principal, Viscogliosi Bros., LLC

MODERATOR: Joanna Lin, Partner, McDermott Will & Emery

4:00 – 4:45 pm

TRANSACTION TRENDS IN ASIA

This panel, led by McDermott's life sciences team in Singapore, will focus on transactional trends in the AIPAC region, including how these trends are impacted by litigation and government investigations.

- Shu Min Ho, Consultant, McDermott Will & Emery
- Rich Smith, Counsel, McDermott Will & Emery
- Susan Wang, Senior Vice President, Asieris Pharmaceuticals

MODERATOR: Yuet Ming Tham, Partner, McDermott Will & Emery

4:45 – 6:30 pm

NETWORKING COCKTAIL RECEPTION

AGENDA

FRIDAY, APRIL 29, 2022
LIFE SCIENCES INVESTMENT FORUM

All times are displayed in EDT

8:30 – 9:15 am — *REGISTRATION & NETWORKING*

9:15 – 9:45 am — FIRESIDE CHAT: THE FOUNDER & FUNDER PERSPECTIVE ON TRENDS & OPPORTUNITIES

Depicting the interplay between fundraising companies and investors, this panel applies first hand experience with a look at what to expect in the year ahead.

- Luba Greenwood, CEO, Kojin Therapeutics
- Adam Koppel, Managing Director, Life Sciences, Bain Capital

9:45 – 10:30 am — UNDERSTANDING INVESTORS' RIGHTS IN SERIES SEED & SERIES A TRANSACTION DOCUMENTS—TERM SHEETS

This session will focus on key considerations for investors participating in investment rounds for early stage life sciences companies.

- Mark Mihanovic, Partner & Co-Head of Transactions, McDermott Will & Emery
- Joanna Lin, Partner, McDermott Will & Emery
- Wasim Malik, Managing Partner, Iaso Ventures
- Isaac Stoner, CEO, Octagon Therapeutics

10:30 – 10:45 am — *NETWORKING BREAK*

10:45 – 11:30 am — VENTURE DEBT & OTHER FINANCING SOLUTIONS TO SCALE FOR GROWTH

This panel will focus on alternative approaches to securing growth capital, from venture debt to IP-secured financing options.

- Ed McNamara, SVP & Senior Business Development Officer, Bridge Bank
- Angus McQuilken, Industry Relations Executive of Life Sciences, McDermott Will & Emery
- Danielle Silva, Assistant Vice President, Capital Advisors Group
- Steve Gatto, Chairman and CEO, Entrinsic Bioscience

11:30 am – 12:15 pm — SYNDICATING WITH STRATEGICS: COLLABORATING WITH CVCS ON INVESTMENTS

Closing out the day is a fireside chat focused on opportunities for investors, entrepreneurs and other players in the life sciences ecosystem to interact and collaborate with the investment arms of industry leading companies.

- Oliver Keown, Managing Director, Intuitive Ventures
- Justin Feng, Senior Associate, MRL Ventures

MODERATOR: Sharon Lamb, Partner, McDermott Will & Emery

12:15 – 1:00 pm — *NETWORKING LUNCH*

EVENT PARTNERS

MARQUEE

AON

BDO

PATRON

ABI LAB

CAPITAL ADVISORS GROUP

CATaiLYST

EXHIBITOR

BridgeBank

WOMEN'S BREAKFAST PARTNERS

THE DEAL MAKHERS

ISPE. | WOMEN IN PHARMA

MassMEDIC THE HEART OF HEALTHTECH

MedtechWOMEN Leaders Advancing Healthcare

PUBLICITY PARTNERS

kotra Korea Trade-Investment Promotion Agency

MassBio Massachusetts Biotechnology Council

MassMEDIC THE HEART OF HEALTHTECH

North Shore InnoVentures Innovate Faster, Climb Higher

Life Science Nation Connecting Products, Services & Capital

BioXchange

GUEST FACULTY

Richie Bavasso
Founder & CEO, nQ Medical

Michael Bayewitch
Executive Director, International Business Development, Simcere Pharma

Jonathan Behr
Partner, SV Health Investors

Jens Bitsch-Norhave
Vice President, Transactions, J&J Innovation

Nancy Briefs
Co-Founder, President & CEO, AltrixBio

Dennis Crowley
Executive Vice President, Corporate Development, Corza Medical

Perry De Fazio
Vice President, Convington Associates

Somjeet Dey
Business Development Operations, Otsuka

Anna Elliott
Managing Director & Partner, Vertess

Paul Fehlner
Senior Vice President, Chief Legal Officer & Corporate Secretary, Axcella

Justin Feng
Senior Associate, MRL Ventures

Aaron Gani
Founder & CEO, BehaVR

Alex Gasner
Executive Vice President, Roivant Health

Neal Gordon, PhD
Managing Director, Bioprocess Technology Group, BDO

Steve Gatto
Chairman and CEO, Entrinsic Bioscience

Luba Greenwood
CEO, Kojin Therapeutics

Joel Gross
Principal, Specialized Tax Services Group, BDO

Meryl Holt
Senior Counsel, Cadence

Brian Johnson
President, MassMEDIC

Sree Kant
Founder & CEO, Bakx Therapeutics

Oliver Keown
Managing Director, Intuitive Ventures

Sean Kinsman
Chief Clinical Officer, RecoveryOne

Adam Koppel
Managing Director, Life Sciences, Bain Capital

Ashleigh Kyle
Associate General Counsel, Becton Dickinson

Wasim Malik
Managing Partner, Iaso Ventures

Marina Massingham
CEO, Aifred Health

John Mayfield
Vice President, Corporate & Business Development, EQRx

Ed McNamara
SVP & Senior Business Development Officer, Bridge Bank

Sapna Mehtani
Lead Counsel, IP, Takeda

Alidad Mireskandari
Chief Development Officer, Interpace Diagnostics

Imran Nasrullah
Head of Licensing, Bayer

Vipul Patel
Managing Director, AON M&A and Transaction Solutions

Deniz Razon
Chief Business Officer, Servier Pharmaceuticals

Bruce Robertson
Managing Director, H.I.G. BioHealth Partners

Audrey Rojas
Co-Leader, US Risk Transaction Advisory Services, Aon

Alif Saleh
CEO, Scipher Medicine

Jeff Schwartz
Managing Director, Life Sciences, Bain Capital

Milan Shah
Chief Technology Officer, Biofourmis

Danielle Silva
Assistant Vice President, Capital Advisors Group

Stefan Spazek
EVP & Director of Debt Placement, Capital Advisors Group

Mark Stencik
Head of Transactions & Executive Director, Business Development, Merck

Isaac Stoner
CEO, Octagon Therapeutics

Jonas Svedlund
Vice President & Deputy General Counsel, Thermo Fisher Scientific Technology Association

Karen Tepichin
General Counsel, Ginkgo Bioworks

John Urquhart
Senior Managing Director, Healthcare Royalty Partners

Marc Viscogliosi
Principal, Viscogliosi Bros., LLC

Sally Wang
VP of Business Development & Head of Global Business Unit, PepLib

Susan Wang
Senior Vice President, Asieris Pharmaceuticals

J.C. Wetzel
Director, Thompson Street Capital Partners

Michael Wolf
Vice President, Deputy General Counsel, Baxter

McDERMOTT FACULTY

Doug Carsten
Partner & Co-Chair of Life Sciences, McDermott Will & Emery

Jiayan Chen
Partner, McDermott Will & Emery

Michael Darowski
Partner, McDermott Will & Emery

Gary Howes
Partner, McDermott Will & Emery

Marshall Jackson
Partner, McDermott Will & Emery

Byron Kalogerou
Partner, McDermott Will & Emery

Sharon Lamb
Partner, McDermott Will & Emery

Joanna Lin
Partner, McDermott Will & Emery

Lisa Mazur
Partner & Co-Chair of Digital Health, McDermott Will & Emery

Angus McQuilken
Industry Relations Executive of Life Sciences, McDermott Will & Emery

Mark Mihanovic
Partner & Co-Head of Transactions, McDermott Will & Emery

Vernessa Pollard
Partner & Co-Chair of Life Sciences, McDermott Will & Emery

Mike Ryan
Partner, McDermott Will & Emery

David Santangelo
Partner, McDermott Will & Emery

Michael Sheehan
Partner, McDermott Will & Emery

Michael Siekman
Partner, McDermott Will & Emery

Rich Smith
Counsel, McDermott Will & Emery

Yuet Ming Tham
Partner, McDermott Will & Emery

Emmanuelle Trombe
Partner, McDermott Will & Emery

Dale Van Demark
Partner, McDermott Will & Emery

Krist Werling
Partner & Co-Head for Private Equity, McDermott Will & Emery

Eleanor West
Partner, McDermott Will & Emery

Shu Min Ho
Consultant, McDermott Will & Emery

UPCOMING EVENTS

VALUE INVESTING FORUM

MAY 4, 2022
NEW YORK, NY

McDERMOTT DIGITAL HEALTH FORUM

MAY 19, 2022
NEW YORK, NY



BIO BASH

JUNE 14, 2022
SAN DIEGO, CA



AHLA ANNUAL RECEPTION

JUNE 28, 2022
CHICAGO, IL




HPE EUROPE

SEPTEMBER 29, 2022
LONDON, UK



EUROPEAN HEALTH & LIFE SCIENCES SYMPOSIUM

OCTOBER 18, 2022
PARIS, FR



HOSPITAL & HEALTH SYSTEM INNOVATION SUMMIT

OCTOBER 20, 2022
NEW YORK, NY

HPE NEW YORK

OCTOBER 21, 2022
NEW YORK, NY





mwe.com

©2022 McDermott Will & Emery. McDermott Will & Emery conducts its practice through separate legal entities in each of the countries where it has offices. For a complete list visit mwe.com/legalnotices. This may be considered attorney advertising. Prior results do not guarantee a similar outcome.

McDermott
Will & Emery